A Pilot Open-Label Study to Examine the Safety and Efficacy of Oral LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Who Have Been Previously Treated With Non-LDE225 Smoothened Inhibitor(s)
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2017
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 14 Sep 2016 Status changed from discontinued to completed.
- 06 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.